Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
MINERVA SURGICAL INC (UTRS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/13/2023 |
8-K
| Quarterly results |
| 09/28/2023 |
SC 13E3
| Form SC 13E3 - Going private transaction by certain issuers: |
| 09/28/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 09/28/2023 |
8-K
| Quarterly results |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/02/2023 |
8-K
| Quarterly results |
| 07/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/06/2023 |
SC 13D/A
| Accelmed Partners II L.P. reports a 69.1% stake in Minerva Surgical, Inc. |
| 05/10/2023 |
SC 13G/A
| AWM Investment Company, Inc. reports a 1.2% stake in Minerva Surgical, Inc. |
| 05/03/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/01/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 03/22/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/21/2023 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I...|
Docs:
|
"Minerva Surgical, Inc. Statements of Operations Years Ended December 31, 2022 2021 Revenues $ 50,294 $ 52,103 Cost of goods sold 23,052 21,580 Gross profit 27,242 30,523 Operating expenses Sales and marketing 38,328 32,193 General and administrative 14,370 22,183 Research and development 5,443 5,292 Total operating expenses 58,141 59,668 Loss from operations Interest income 89 10 Interest expense Change in fair value of derivative liabilities - 38,007 Loss on extinguishment of convertible notes - Gain on extinguishment of PPP loan - 3,036 Other expense, net Net loss before income taxes Income tax expense Net loss $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ Weighted-average common shares used in computing net loss per share, basic and dilute...",
"RELATED LINKS https://www.aubandme.com https://www.minervasurgical.com" |
|
| 03/13/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/14/2023 |
SC 13G
| AWM Investment Company, Inc. reports a 5.6% stake in Minerva Surgical, Inc. |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
8-K
| Appointed a new director|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Amended and Restated Certificate of Incorporation of Minerva Surgical, Inc.",
"Amended and Restated Bylaws of Minerva Surgical, Inc.",
"Registration Rights Agreement, by and between Minerva Surgical, Inc., Accelmed Partners II L.P. and New Enterprise Associates 13, L.P",
"Minerva Surgical Closes $30 Million Private Placement of Common Stock Santa Clara, Calif. - February 9, 2023 - Minerva Surgical, Inc. , a women's health company focused on the treatment of Abnormal Uterine Bleeding , announced today that it has closed on the sale of 146,627,565 shares of its common stock in a private placement, led by Accelmed Partners , with participation by New Enterprise Associates, at an offering price of $0.2046 per share. Accelmed is now the controlling stockholder of Minerva Surgical. Gross proceeds of the private placement are approximately $30 million, before deducting placement agent fees and other expenses payable by Minerva Surgical. Piper Sandler acted as sole placement agent for the private placement. Minerva Surgical intends to use the net proceeds from the ..." |
|
| 02/09/2023 |
SC 13D
| Accelmed Partners II L.P. reports a 69.3% stake in Minerva Surgical, Inc. |
| 01/24/2023 |
SC 13D/A
| NEW ENTERPRISE ASSOCIATES 13 LP reports a 33.5% stake in Minerva Surgical, Inc. |
| 01/23/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 01/17/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/17/2023 |
8-K
| Quarterly results |
| 01/13/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 12/30/2022 |
8-K
| Quarterly results |
| 12/28/2022 |
8-K
| Quarterly results |
| 12/28/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 12/28/2022 |
8-K
| Quarterly results |
| 11/15/2022 |
8-K/A
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/02/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/09/2022 |
8-K
| Quarterly results|
Docs:
|
"Minerva Surgical, Inc. Condensed Statements of Operations Three Months Ended June 30 Six Months Ended June 30 2022 2021 2022 2021 Revenues $ 12,967 $ 14,114 $ 23,902 $ 25,952 Cost of goods sold 5,322 5,382 10,844 10,387 Gross profit 7,645 8,732 13,058 15,565 Operating expenses Sales and marketing 9,691 8,497 19,164 14,964 General and administrative 1,579 10,125 6,564 14,128 Research and development 1,274 1,673 2,529 2,824 Total operating expenses 12,544 20,295 28,257 31,916 Loss from operations Interest income 19 — 28 — Interest expense Change in fair value of derivative liabilities — — Gain on extinguishment of PPP loan — 3,036 — 3,036 Other income , net 48 Net loss before income taxes Income tax benefit — — — — Net loss $ $ $ $ Net loss per share attributable to common stockholde..." |
|
|
|
|